Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Burke, VA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Burke, VA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Mesa, AZ
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Elkridge, MD
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Elkridge, MD
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Endwell, NY
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Endwell, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Jefferson Hills, PA
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Jefferson Hills, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Coquitlam,
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Coquitlam,
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Boca Raton, FL
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Lexington, KY
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Metairie, LA
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Boston, MA
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Omaha, NE
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Binghamton, NY
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Binghamton, NY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Elmira, NY
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Elmira, NY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Syracuse, NY
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Raleigh, NC
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Angelo, TX
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Angelo, TX
Click here to add this to my saved trials
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Decin,
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Decin,
Click here to add this to my saved trials
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Mesa, AZ
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics (Version 1 23Aug2018)
Status: Enrolling
Updated:  12/31/1969
The Hope Clinic of the Emory Vaccine Center
mi
from
Atlanta, GA
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics (Version 1 23Aug2018)
Status: Enrolling
Updated: 12/31/1969
The Hope Clinic of the Emory Vaccine Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bardstown, KY
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Metairie, LA
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newton, KA
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newton, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Metairie, LA
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Warwick, RI
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 8400013
mi
from
Augusta, KY
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 8400013
mi
from
Augusta, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Jordan, UT
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated:  12/31/1969
mi
from
Montreal,
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Status: Enrolling
Updated: 12/31/1969
mi
from
Montreal,
Click here to add this to my saved trials
Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP
Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northwest
mi
from
Portland, OR
Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP
Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northwest
mi
from
Portland, OR
Click here to add this to my saved trials
Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP
Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years
Status: Enrolling
Updated:  12/31/1969
Baylor Scott & White Health
mi
from
Temple, TX
Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP
Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years
Status: Enrolling
Updated: 12/31/1969
Baylor Scott & White Health
mi
from
Temple, TX
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Vaccine Research & Education Unit
mi
from
Iowa City, IA
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Vaccine Research & Education Unit
mi
from
Iowa City, IA
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
University of Maryland Baltimore - School of Medicine - Medicine
mi
from
Baltimore, MD
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
University of Maryland Baltimore - School of Medicine - Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
Saint Louis University - Center for Vaccine Development
mi
from
Saint Louis, MO
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
Saint Louis University - Center for Vaccine Development
mi
from
Saint Louis, MO
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center - Infectious Diseases
mi
from
Cincinnati, OH
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center - Infectious Diseases
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center - Infectious Diseases
mi
from
Nashville, TN
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center - Infectious Diseases
mi
from
Nashville, TN
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)
mi
from
Galveston, TX
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)
mi
from
Galveston, TX
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine - Molecular Virology and Microbiology
mi
from
Houston, TX
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine - Molecular Virology and Microbiology
mi
from
Houston, TX
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases
mi
from
Seattle, WA
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases
mi
from
Seattle, WA
Click here to add this to my saved trials
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated:  12/31/1969
Emory Children's Center - Pediatric Infectious Diseases
mi
from
Atlanta, GA
2017 A/H7N9 IIV Revaccination
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Enrolling
Updated: 12/31/1969
Emory Children's Center - Pediatric Infectious Diseases
mi
from
Atlanta, GA
Click here to add this to my saved trials